Sirona Biochem Announces 2023 Annual Meeting Results
29 March 2024 - 8:00AM
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
(“
Sirona”) announces the voting results from its
Annual General Meeting of Shareholders (the "Meeting"), held in
Vancouver, British Columbia on March 28, 2024. The total number of
shares represented by shareholders present in person and by proxy
at the Meeting was 26,722,196, representing 10.52% of Sirona's
issued and outstanding Common Shares.
All matters put forward to shareholders for
consideration and approval, as set out in the Company's Management
Information Circular dated 22nd of February, 2024, were approved by
the requisite majority of votes cast at the Meeting. These
were:
1. To elect Sirona’s board of directors; 2. to
fix the number of directors of the Company at five; 3. to appoint
Davidson & Company LLP, Chartered Professional Accountants, as
the Company’s auditor for the ensuing year and authorize the
directors to set the auditor’s remuneration; and 4. to confirm and
approve the Company’s existing stock option plan.
Sirona would like to thank all shareholders for
their continued support.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug
discovery company with a proprietary platform technology. Sirona
specializes in stabilizing carbohydrate molecules with the goal of
improving efficacy and safety. New compounds are patented for
maximum revenue potential.
Sirona’s compounds are licensed to leading
companies around the world in return for licensing fees, milestone
fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is
located in France and is the recipient of multiple French national
scientific awards and European Union and French government grants.
For more information, please visit www.sironabiochem.com.
For more information regarding this press
release, please contact:
Investor Enquiries: Christopher
Hopton CPAEmail: chopton@sironabiochem.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sirona Biochem cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements. Forward-looking
statements are only predictions based upon current expectations and
involve known and unknown risks and uncertainties. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of release of the
relevant information, unless explicitly stated otherwise. Actual
results, performance or achievement could differ materially from
those expressed in, or implied by, Sirona Biochem’s forward-looking
statements due to the risks and uncertainties inherent in Sirona
Biochem’s business including, without limitation, statements about:
the progress and timing of its clinical trials; difficulties or
delays in development, testing, obtaining regulatory approval,
producing and marketing its products; unexpected adverse side
effects or inadequate therapeutic efficacy of its products that
could delay or prevent product development or commercialization;
the scope and validity of patent protection for its products;
competition from other pharmaceutical or biotechnology companies;
and its ability to obtain additional financing to support its
operations. Sirona Biochem does not assume any obligation to update
any forward-looking statements except as required by law.
TSX-V: SBM
www.sironabiochem.com
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Oct 2023 to Oct 2024